Har­vard 'MacArthur ge­nius’ Kevin Eggan steps in to run ear­ly-stage re­search at rare dis­ease spe­cial­ist Bio­Marin

Pi­o­neer­ing ALS re­searcher Kevin Eggan has a new gig.

Af­ter hold­ing a tenured po­si­tion at Har­vard while work­ing at the Broad and play­ing a founder’s role in launch­ing 3 biotechs, Eggan is tak­ing up a job run­ning ear­ly-stage re­search at Bio­Marin, the rare dis­ease biotech still feel­ing the sting of a re­jec­tion at the hands of the FDA.

Eggan played a high-pro­file role do­ing stem cell re­search, and is cred­it­ed with help­ing spur the launch of Quralis, En­Clear and Q-State, draw­ing in $85 mil­lion in in­vestor sup­port along the way. He’s done ground­break­ing work on ALS, par­tic­u­lar­ly in build­ing dis­ease mod­els for the ail­ment, and Bio­Marin spot­light­ed his in­volve­ment in an­ti-Tau re­search that Bio­gen is us­ing to build an Alzheimer’s pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER